Kura Oncology is a commercial-stage biopharmaceutical company focused on precision oncology, primarily in blood cancers. Its lead product, KOMZIFTI (ziftomenib), is an oral once-daily menin inhibitor approved by the FDA in late 2025 for adults with relapsed or refractory acute myeloid leukemia (AML) harboring an NPM1 mutation. KOMZIFTI works by blocking the interaction between menin and KMT2A proteins that drive leukemic growth; NPM1 mutations represent roughly 30% of all AML cases. Kura sells KOMZIFTI through a specialty distribution network in the U.S., targeting roughly 4,000 oncology accounts, with a field force of 60+ oncology account managers operating alongside co-promotion partner Kyowa Kirin. Kura records all U.S. net revenue from KOMZIFTI, then splits profits and losses 50/50 with Kyowa Kirin, which also pays tiered double-digit royalties on ex-U.S. sales. Kura is also eligible for up to $1.161B in milestones under the Kyowa Kirin collaboration. Beyond the approved indication, Kura is running Phase 3 trials of ziftomenib in frontline AML, where longer treatment duration would significantly increase revenue per patient. The pipeline also includes ziftomenib combinations with FLT3 inhibitors in AML, a Phase 1 program in gastrointestinal stromal tumors, and a secondary platform of farnesyl transferase inhibitors (FTIs) being evaluated in renal cell carcinoma and KRAS-mutated solid tumors.